News & Updates

Show Multimedia Only
Sotrovimab benefits select hospitalized COVID-19 patients
Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026 byAudrey Abella

In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.

Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026 byStephen Padilla

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.

Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026
Maternal asthma may raise congenital heart defect risk in offspring
Maternal asthma may raise congenital heart defect risk in offspring
15 Jan 2026 byStephen Padilla

Asthma and allergic tendency in mothers appear to elevate the risk of congenital heart defect (CHD) in their children, suggests a study, noting that nonallergic asthma also contributes to such risk.

Maternal asthma may raise congenital heart defect risk in offspring
15 Jan 2026